PSMA-PET and the Evolving Imaging Paradigm in Prostate Cancer

PSMA-PET imaging has successfully disrupted the prostate cancer paradigm and experts agree that unleashing the full potential of this breakthrough requires a multidisciplinary approach.

“I think that having the clinical context such as the PSA, the Gleason score, the other features that assess the aggressiveness of the disease can really help with some of these subtle findings that can be found on PET imaging,” says Daniel Spratt, MD.

Daniel Spratt, MD, highlights the evolving paradigm of PET-based imaging agents in prostate cancer, with a focus on the impact of PSMA-PET imaging.

Jaideep S. Sohi, MD, discusses the challenges with the use of conventional imaging in prostate cancer and how PSMA-PET alleviates these issues.

In this video, Jaideep S. Sohi, MD, explains factors to consider regarding the timing of re-imaging with PSMA-PET in patients with prostate cancer.

In this video, Jaideep S. Sohi, MD, explains how the expanded information provided by PSMA-PET imaging allows physicians to more accurately tailor treatment plans for patients.

Jaideep S. Sohi, MD, shares his vision for the future of PSMA-PET imaging in prostate cancer.